

# Development of HMGCLL1 inhibitory small molecule CML therapeutic anticancer drug

Samsung Medical Center



ONCOLOGY	Lead
Product Type	Peptide product
Indication	1st indication: Leukemia, Myelogenous, Chronic, BCR-ABL Positive [MeSH term]
Target	3-hydroxy-3-methylglutaryl-CoA
MoA(Mechanism of Action)	G0/G1 phase cell cycle arrest through CDK4/6-mediated inhibition
Competitiveness	First In Class
Development Stage	Lead
Route of Administration	Not decided yet